© Reuters. Stallergenes Greer: review of annual goals and objectives
Stallergenes Greer, a biopharmaceutical company specializing in respiratory allergies, announcing estimating now that it will achieve by 2018 a turnover of between 270 and 280 million euros, and EBITDA of between 40 and 50 million.
This is an update of the forecasts published on 22 march, which announced a growth in turnover in the range of average revenue and EBITDA in excess of the 21.9 million euros recorded in 2017.
‘The revised expectations reflect efficiency gains, faster than expected and good business performance during the first months of the year, as well as a clarification of the market access conditions in Europe,’ she explains.
Copyright (c) 2018 CercleFinance.com. All rights reserved.